NATERA, INC.

Public Equity (NASDAQ)PublicDiagnosticsNASDAQ

📍 Austin, TX, USA• Founded 2004

StreetZero Signal 55

Be the first to signal interest

About NATERA, INC.

Natera, Inc. is a global leader in cell-free DNA testing with a focus on reproductive health, oncology, and organ transplantation. The company develops and commercializes non-invasive tests that analyze DNA to inform clinical decisions. It is publicly traded on NASDAQ under the ticker NTRA.

LATEST FUNDINGRule 144

$78K

Announced 2026-10-28

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for NATERA, INC..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

EMPLOYEES—

FOUNDED2004

HQAustin, TX, USA

Industry

Public Equity (NASDAQ)

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Publicly traded genetic testing company on NASDAQ (NTRA).
Specializes in cell-free DNA tests for reproductive health and oncology.
Rule 144 filing reflects routine restricted-share transaction, not new capital raise.

Ask StreetZero about NATERA, INC.

Put our AI to work on this deal.

What is NATERA, INC.'s value proposition?Who are NATERA, INC.'s competitors?Why does this raise matter?Summarize NATERA, INC. for an investor.

Similar companies

Other Public Equity (NASDAQ) deals, ranked by Signal.

Paylocity Holding Corporation

$66.0M

BENTLEY SYSTEMS INC

$67.5M

Crowdstrike Holdings, Inc.

$141.0M

Palo Alto Networks Inc

$201.4M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.